53.53

2.46% -1.35

After Hours: 53.23 -0.30 -0.56%

Crispr Therapeutics Ag (CRSP)

Overview News Price History Option Chain Financials Why CRSP Down? Discussions Forecast

Crispr Therapeutics Ag stock is traded at $53.53, with a volume of 1.47M. It is down -2.46% in the last 24 hours and down -17.34% over the past month. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Previous Close:

$54.88

Open:

$55.04

24h Volume:

1.47M

Relative Volume:

0.46

Market Cap:

$4.87B

Revenue:

$170.10M

Net Income/Loss:

$-239.59M

P/E Ratio:

-19.12

EPS:

-2.8

Net Cash Flow:

$-191.20M

1W Performance:

+0.87%

1M Performance:

-17.34%

6M Performance:

+22.72%

1Y Performance:

+10.97%

1-Day Range:

$53.25

$55.30

1-Week Range:

$52.07

$55.30

52-Week Range:

$30.04

$71.13

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name

Crispr Therapeutics Ag

Sector

Healthcare (1147)

Industry

Biotechnology (644)

Phone

(617) 315-4600

Address

BAARERSTRASSE 14, ZUG

Employee

393

Twitter

@crisprtx

Next Earnings Date

2024-12-05

Latest SEC Filings

CRSP's Discussions on Twitter

Compare CRSP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRSP Crispr Therapeutics Ag	53.53	4.99B	170.10M	-239.59M	-191.20M	-2.80
VRTX Vertex Pharmaceuticals Inc	389.08	99.27B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	586.96	62.28B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.18	59.14B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	707.96	43.34B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	300.14	36.72B	3.81B	-644.79M	-669.77M	-6.24

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform
Feb-12-25	Upgrade	TD Cowen	Sell → Hold
Feb-03-25	Initiated	H.C. Wainwright	Buy
Aug-06-24	Reiterated	Needham	Buy
Aug-02-24	Initiated	Rodman & Renshaw	Buy
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight
Mar-21-23	Initiated	Bernstein	Mkt Perform
Mar-17-23	Initiated	Bryan Garnier	Buy
Mar-07-23	Initiated	Robert W. Baird	Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-28-22	Initiated	Credit Suisse	Neutral
Dec-07-21	Initiated	Cowen	Market Perform
Oct-19-21	Initiated	SVB Leerink	Outperform
Jun-14-21	Upgrade	Citigroup	Sell → Neutral
Apr-21-21	Upgrade	Jefferies	Hold → Buy
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-10-20	Reiterated	Chardan Capital Markets	Buy
Dec-10-20	Downgrade	Jefferies	Buy → Hold
Dec-10-20	Reiterated	Needham	Buy
Dec-07-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Oct-05-20	Initiated	BofA Securities	Buy
Jul-28-20	Reiterated	Needham	Buy
Jul-14-20	Initiated	SunTrust	Buy
Jun-15-20	Reiterated	Canaccord Genuity	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-03-20	Downgrade	Evercore ISI	Outperform → In-line
Nov-19-19	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-19	Upgrade	Oppenheimer	Perform → Outperform
Aug-01-19	Initiated	Jefferies	Buy
Jul-26-19	Initiated	Canaccord Genuity	Buy
Jun-10-19	Initiated	ROTH Capital	Buy
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-14-19	Initiated	William Blair	Mkt Perform
Jan-28-19	Downgrade	Goldman	Buy → Neutral
Jan-22-19	Downgrade	Citigroup	Neutral → Sell

View All

Crispr Therapeutics Ag Stock (CRSP) Latest News

03:37 AM

Can trapped investors hope for a rebound in CRISPR Therapeutics AGJuly 2025 Gainers & Growth Focused Entry Reports - Newser

03:37 AM

01:38 AM

T. Rowe Price Investment Management Inc. Reduces Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat

01:38 AM

07:04 AM

Technical analysis overview for CRISPR Therapeutics AG stockJuly 2025 Macro Moves & Stepwise Trade Signal Implementation - Newser

07:04 AM

06:47 AM

Predicting CRISPR Therapeutics AG trend using moving averagesQuarterly Portfolio Report & Precise Entry and Exit Recommendations - Newser

06:47 AM

06:21 AM

CRISPR Therapeutics: A Speculative Buy With Promising Potential Ahead (CRSP) - Seeking Alpha

06:21 AM

03:27 AM

Multi asset correlation models including CRISPR Therapeutics AGStock Surge & Free Safe Entry Trade Signal Reports - Newser

03:27 AM

03:21 AM

Charles Schwab Investment Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP - MarketBeat

03:21 AM

Aug 26, 2025

Statistical indicators supporting CRISPR Therapeutics AG’s strength2025 Trading Volume Trends & Community Trade Idea Sharing - Newser

Aug 26, 2025

Comparing CRISPR Therapeutics AG in custom built stock radarsTrade Analysis Summary & Long-Term Capital Growth Strategies - Newser

Aug 26, 2025

Is it time to cut losses on CRISPR Therapeutics AGJuly 2025 Weekly Recap & Fast Momentum Entry Tips - Newser

Aug 26, 2025

Is CRISPR Therapeutics AG stock reversal real or fakeJuly 2025 Volume & Trade Opportunity Analysis - Newser

Aug 26, 2025

What makes CRISPR Therapeutics AG stock price move sharply2025 Market Outlook & Capital Efficient Trade Techniques - Newser

Aug 26, 2025

CRISPR Therapeutics AG recovery potential after sell offJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser

Aug 26, 2025

Vanguard Group Inc. Acquires 33,711 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Aug 26, 2025

Analyzing recovery setups for CRISPR Therapeutics AG investorsPortfolio Return Report & Fast Gain Swing Trade Alerts - Newser

Aug 26, 2025

Aug 25, 2025

Published on: 2025-08-25 19:59:28 - Newser

Aug 25, 2025

Technical Models Detect Momentum Build in CRISPR Therapeutics AGJuly 2025 PreEarnings & Daily Momentum Trading Reports - 더경남뉴스

Aug 25, 2025

Crispr Therapeutics: Sell Before It's Too Late (NASDAQ:CRSP) - Seeking Alpha

Aug 25, 2025

H.C. Wainwright Lifts CRISPR Therapeutics’ (CRSP) Price Target on CASGEVy Sales Growth - MSN

Aug 25, 2025

CRISPR Therapeutics Raises Price Target to $80 on CASGEVy Sales Growth - AInvest

Aug 25, 2025

Aug 24, 2025

Stop Loss: Does CRISPR Therapeutics AG have pricing powerJuly 2025 Final Week & AI Forecast for Swing Trade Picks - sundaytimes.kr

Aug 24, 2025

Aug 23, 2025

Is CRISPR Therapeutics AG stock bottoming outJuly 2025 Reactions & Breakout Confirmation Trade Signals - Newser

Aug 23, 2025

Will Volume Confirm Reversal in CRISPR Therapeutics AGPortfolio Risk Summary & Reliable Intraday Trade Alerts - 더경남뉴스

Aug 23, 2025